FCM
ADVM

Farallon Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Farallon Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,000
Closed -$14.8M – 299
2021
Q1 		$14.8M Hold
150,000
– – 0.07% 118
2020
Q4 		$16.3M Hold
150,000
– – 0.1% 96
2020
Q3 		$15.4M Buy
+150,000
New +$22.5M 0.11% 91
2015
Q3 		– Sell
-6,500
Closed -$1.06M – 85
2015
Q2 		$1.06M Hold
6,500
– – 0.01% 93
2015
Q1 		$2.63M Buy
+6,500
New +$2.75M 0.04% 84

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Farallon Capital Management's ADVM Position: Q2 2021 in Review

Farallon Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 150,000 shares — an estimated $14.8M sold.

Farallon Capital Management first reported a position in ADVM in Q1 2015 and held it in 5 quarters. The position peaked at $16.3M in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Farallon Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Farallon Capital Management sold 150,000 Adverum Biotechnologies shares in Q2 2021, an estimated $14.8M.
  • Farallon Capital Management first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 5 quarters.
  • Farallon Capital Management's Adverum Biotechnologies position peaked at $16.3M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.